EQRx, Inc. is a pharmaceutical company based in Cambridge, Massachusetts that focuses on developing medicines for the treatment of oncology and immune-inflammatory diseases in the United States. The company's clinical trials consist of pre-registrational programs in Phase III which include Aumolertinib for the treatment of non-small cell lung cancer and Sugemalimab for the treatment of NSCLC. EQRx has other clinical and pre-clinical stage assets in its pipeline, such as Lerociclib, EQ176, and EQ121.